There are currently no medications for the core symptoms of autism. But many autistic people do take drugs for irritability, anxiety, depression, and other co-occurring conditions.
According to a report published by Fortune Business Insights, titled, “Autism Spectrum Disorder Therapeutics Market”: Global Market Analysis, Insights and Forecast, 2018-2026,” the global market is likely to reach US$ 4,612.1 Mn by 2026 owing to the rising incidence of autism spectrum disorder worldwide. The report provides valuable insights into the global market trends and factors that are directly affecting the growth of the market. As per the report, the global autism spectrum disorder therapeutics market was worth US$ 3,293.0 Mn in 2018. Considering the increasing awareness programs regarding this particular disorder and less availability of treatment options, the global market is expected to rise at a moderate CAGR of 4.3% during the forecast period (2019-2026).
Key Players Operating in The Autism Spectrum Disorder Therapeutics Market Include:
Key players are involved in mergers and acquisition to strengthen their market position. Owing to increasing competition frequent innovations are taking place in the market. Some of the companies operating the industry are:Request a Sample Copy of the Research Report:https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/autism-spectrum-disorder-therapeutics-market-101207
- Applied Behavior Consultants,
- Allergan,
- Pfizer Inc.,
- Q BioMed Inc,
- Fusion Autism Center,
- AstraZeneca,
- Hopebridge, LLC.,
- Johnson and Johnson Services, Inc.,
- Behavior Innovations,
- Eli Lilly and Company,
- Otsuka Holdings Co. Ltd.,
- other prominent market players.
